Citius Oncology
United States · Biopharma, Biotechnology, Health Care
Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and
Key facts
- Headquarters
- United States
- Employees
- 19
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (CTOR)
- Website
- citiuspharma.com
- Company page
Recent activity at Citius Oncology
- : SEC 8-K (5.02): On September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders, during which stockholders elected Dr. Eugene Holuka, Robert Smith, and Carol Webb as Class II directors for a three-year term expiring in 2029. The voting results showed significant support for the nominees with over 67 million votes each for, alongside a few million withheld. Additionally, the stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with over 73 million shares voting in favor. This meeting and its outcomes are critical as they affect the governance and future direction of the company.
- : Citius Oncology secures up to $36.5 million in debt and equity capital led by Avenue Capital, advancing LYMPHIR® commercialization efforts.
- : Citius Oncology launched LYMPHIR™ for cutaneous T-cell lymphoma treatment, showcasing early adoption in oncology centers.
- : Citius Oncology announces a $18M fundraise to support the launch of LYMPHIR, a cancer immunotherapy. The offering is backed by a healthcare-focused investor.
- : SEC 8-K (2.01): On December 1, 2025, Citius Oncology, Inc. announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl), a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma. This launch represents a significant strategic move for the company, enhancing its product portfolio and potentially increasing revenues in the oncology market. The approval signifies the company's commitment to providing innovative therapies for challenging health conditions. The press release detailing this launch was issued on the same date, reinforcing the company's public communication efforts.
- : SEC 8-K (5.02): On October 27, 2025, Citius Oncology, Inc. held its annual meeting of stockholders where stockholders approved an amendment to the Company’s 2024 Omnibus Stock Incentive Plan. This Amendment increased the number of shares authorized for issuance under the plan from 15,000,000 to 30,000,000 shares. The Board of Directors had previously approved this Amendment on September 19, 2025, contingent upon stockholder approval. The decision represents a strategic move to enhance the Company’s ability to attract and retain key talent, as it expands the share pool available for stock options and other equity awards.
- : Citius Oncology supports TenX Keane Acquisition with $67K to Extend Deal Deadline
Citius Oncology funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Venture | $36.5M |
| Dec 2025 | Funding Round | $18.0M |
Leadership
- Omar Lansari, Director of Marketing
- John Westman, Vice President Project Management
- Leonard Mazur, Chief Executive Officer
Verified email and direct lines for Citius Oncology’s decision-makers are on Fundz. See plans
Citius Oncology in the news
- Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - prnewswire.com (Feb 13, 2026)
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - prnewswire.com (Feb 11, 2026)
- Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - prnewswire.com (Aug 14, 2026)
- Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - prnewswire.com (May 15, 2026)
- Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - prnewswire.com (Sep 09, 2025)
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - prnewswire.com (Dec 09, 2025)
- Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - prnewswire.com (Mar 31, 2026)
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - prnewswire.com (Dec 01, 2025)
Companies similar to Citius Oncology
- NRx Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Bio-Convert ApS · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Pharma Two B Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Citius Oncology: questions and answers
What does Citius Oncology do?
Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company specializes in the development of novel cancer treatments, including targeted therapies and immunotherapies, designed to improve the effectiveness and safety of cancer care. Citius Oncology operates primarily in the United States and
Where is Citius Oncology headquartered?
Citius Oncology is headquartered in United States.
How many employees does Citius Oncology have?
Citius Oncology has about 19 employees.
Has Citius Oncology raised funding?
Yes. Fundz has recorded 2 funding events for Citius Oncology. The most recent, $36.5M, was in May 2026.
Who leads Citius Oncology?
John Westman is a Vice President Project Management at Citius Oncology.
What is the latest news on Citius Oncology?
On Sep 29, 2026, SEC 8-K (5.02): On September 29, 2026, Citius Oncology, Inc. held its 2026 annual meeting of stockholders, during which stockholders elected Dr. Eugene Holuka, Robert Smith, and Carol Webb as Class II directors for a three-year term expiring in 2029. The voting results showed significant support for
Is Citius Oncology a public company?
Yes. Citius Oncology is publicly traded under the ticker CTOR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy